Fourteen ambulatory and hospitalized patients with primary and secondary Raynaud's phenomenon have been examined before and after a thirty-one-day therapeutic trial.
The treatment was conducted in two cycles. The first one lasted ten days, during which placebo was administered. The second cycle lasted three weeks, during which ketanserin, a selective antagonist of 5-hydroxytryptamine (5-HT2) receptors, was administered.
The therapeutic effect consisted of the complete healing of digital ulcers in 4 of 5 patients and a considerable decrease in the number, length, and severity of daily attacks.
To evaluate the digital blood flow, each patient was submitted to a medical dynamic telethermographic test. This, after the cooling test, demonstrated an average decrease of twenty minutes in the time necessary to reestablish basal thermal conditions (T') at the end of an adequate period of therapy using optimal doses of the drug. The authors affirm that orally administered ketanserin has a beneficial effect and can be well tolerated in subjects with Raynaud's phenomenon.
Get full access to this article
View all access options for this article.
References
1.
Carol A., Terregino BA, Seibold JR: Influence of the menstrual cycle on Raynaud's phenomenon and on cold tolerance in normal women. Angiology36(2):88, 1985.
2.
Meldrum DR, Deftos LJ, Henderson BE: Estrogen replacement therapy: Indications and complications. Ann Intern Med98:195, 1983.
3.
Rossi G.: Il Raynaud, fenomeno e malattia. Il Polso4:53, 1983.
4.
Fries JF: The microvascular pathogenesis of sclerodermia. Ann Intern Med91:788, 1979.
5.
Harper FE, et al: A prospective study of Raynaud's phenomenon and early connective tissue disease. Am J Med72:883, 1982.
6.
Kalienberg Cgm , Wouda AA: The TH: Systemic involvement and immunologic findings in patients with Raynaud's phenomenon. Am J Med69:675, 1980.
7.
Halpern A., Kuhn PH, Shaftel HE: Raynaud's phenomenon and serotonin. Angiology2:151, 1960.
8.
Winkelmann RK , Goldyne ME, Linscheid RL: Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol95:51, 1976.
9.
Allegra C., Tanelli V.: Results of a double-blind placebo-controlled study with a serotonin selective antagonist (ketanserin) in the treatment of 30 patients with acrocyanotic syndrome. Clin Ter Cardiovasc1, 1985.
10.
Hellemans H., et al: Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disease. A double-blind placebo-controlled crossover trial. Center for Thrombosis and Vascular Research and Division of Rheumatology, Department of Internal Medicine, University of Leuven , Belgium.
11.
Janssen Paj: The pharmacology of specific, pure and potent serotonin 5-HT2 or S-antagonist. In: Advances of Pharmacology and Therapeutics , vol. 4, ed. by Yoshida H, Ebash S.Oxford, New York, Pergamon Press , 1982, p. 21.
12.
Roald PK, Seem E.: Trattamento del fenomeno di Raynaud con Ketanserina in pazienti affetti da connettiviti diffuse. Br Med J318, 1984.
13.
Seibold JR, Jageneau Ahm: Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist . Arthritis and Rheumatism27:139, 1984.
14.
Stranden E. , Roald OK, Krohg K.: Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin. Br Med J285:1069, 1982.
